Temozolomide for treating brain metastases.

[1]  G. Margison,et al.  Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. , 2000, The Journal of pharmacology and experimental therapeutics.

[2]  P. Beale,et al.  Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies , 1999, British Journal of Cancer.

[3]  G. Weiss,et al.  Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. V. Von Hoff,et al.  A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  B. Dörken,et al.  Brain metastases in breast cancer: prognostic factors and management. , 1999, European journal of cancer.

[6]  K. Kelly,et al.  Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? , 1998, Lung cancer.

[7]  A. Gregor,et al.  The treatment of brain metastases from lung cancer. , 1998, Lung cancer.

[8]  H. Minn,et al.  Prognosis of patients treated for intracranial metastases with whole-brain irradiation. , 1998, Annals of medicine.

[9]  E. Arbit,et al.  Surgical treatment of 70 patients with brain metastases from breast carcinoma , 1997, Cancer.

[10]  W. Hall,et al.  Brain metastases: Histology, multiplicity, surgery, and survival , 1996 .

[11]  B. Young,et al.  Demographics of brain metastasis. , 1996, Neurosurgery clinics of North America.